Skip to main content
Signal8

Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association

$CRDLPress releaseMay 7, 2026, 7:27 AM ETRead the release

Cardiol Therapeutics announced that Phase II MAvERIC results for CardiolRx™ in recurrent pericarditis were accepted for publication in the Journal of the American Heart Association. The study demonstrated rapid reductions in pain and inflammation with a favorable safety profile, providing clinical validation for the ongoing pivotal Phase III MAVERIC trial which is over 75% enrolled.

Key figures

Drug Name
CardiolRx™
Phase Of Trial
Phase II
Enrollment percentage
> 75%

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.